Semax

Overview

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) developed at the M.M. Shemyakin Institute and Moscow State University. It is structurally derived from adrenocorticotropic hormone fragment ACTH(4-10), with a C-terminal Pro-Gly-Pro tripeptide added for proteolytic stability.

Research Background

Semax is widely used in Eastern European neuropharmacology research and has been studied in models of cerebral ischemia, cognitive function, stress response, and neuroplasticity. It does not engage the corticotropic axis despite its ACTH-derived sequence.

Storage & Handling

Store lyophilized peptide at -20°C for long-term stability. Once reconstituted with bacteriostatic water, store at 2–8°C and use within recommended timeframes. Handle under sterile laboratory conditions and avoid repeated freeze-thaw cycles.

Disclaimer:
This product is for laboratory research use only. It is not intended for human or animal consumption or for use in any diagnostic, therapeutic, or clinical applications.

Semax exerts neuromodulatory effects without activating melanocortin receptors at typical research concentrations. Studies indicate it upregulates expression of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), modulates dopaminergic and serotonergic systems, and influences enkephalin and HPA-axis signaling. It is reported to cross the blood-brain barrier and produce CNS effects in published animal-model research.

Semax is studied in research on cerebral ischemia, cognitive function, stress, neuroplasticity, and neurotrophic factor biology. It is a reference peptide in the broader category of ACTH-derived nootropic research.